Business Description
Insilico Medicine is a biotechnology company that uses artificial intelligence to speed up the discovery and development of new drugs, with operations across Hong Kong, the United States, the United Kingdom, China, and other markets. The company focuses on treatments for serious conditions such as cancer, fibrosis, infectious diseases, and disorders of the brain and immune system. Its flagship product, the Pharma.AI platform, is an end-to-end software tool that helps pharmaceutical researchers work more efficiently and produce better results. Founded in 2014 and headquartered in Hong Kong's New Territories, the company also works with partners including Liquid AI and ASKA Pharmaceutical to expand its research into areas such as lightweight AI models and hard-to-treat gynecological conditions.
